Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab in pediatric Crohn's disease
jRCT2051230129Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised trial of mirikizumab in Crohn's disease (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Percentage of participants with clinical response by PCDAI at Week 12 and endoscopic response by SES-CD at Week 52 and Percentage of participants with clinical response by PCDAI at Week 12 and clinical remission by PCDAI at Week 52. Started Jun 2024; status: recruiting.
02
Drugs
mirikizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2051230129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230129.